Talaris Therapeutics, Inc. announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the company's board of directors. Dr. Smith joins the company team with over 20 years of biopharmaceutical industry experience overseeing more than 50 clinical trials and more than 20 regulatory approvals leading to global product launches of small molecules, biologics and devices. Dr. Smith currently serves as the Chief Medical Officer at Novosteo, Inc. and as a member of the Board of Directors of Sangamo Therapeutics, Inc., Capstan Therapeutics and Antares Pharma, Inc. The company also announced that Nicholas Galakatos, Ph.D., has retired from its Board.

Dr. Galakatos is Global Head of Life Sciences at Blackstone and has served as a board member of the company since 2018.